TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality
Our findings revealed the dual-functional significance of TPX2 in controlling DNA DSB repair pathway choice and mitotic progression, suggesting a potential therapeutic strategy involving PARPi for patients with pancreatic cancer.
Authors
- Xuhui Tong
- Di Wu (ORCID: https://orcid.org/0000-0001-9640-0516)
- Jin Xu (ORCID: https://orcid.org/0000-0002-2942-8604)
- Yubin Lei (ORCID: https://orcid.org/0000-0002-4468-8076)
- Yalan Lei
- Mingming Xiao (ORCID: https://orcid.org/0000-0003-0862-2501)
- Si Shi (ORCID: https://orcid.org/0000-0002-6652-0629)
- Zhilong Ma (ORCID: https://orcid.org/0000-0002-6946-8686)
- Xianjun Yu (ORCID: https://orcid.org/0000-0002-6697-7143)
- Wei Wang (ORCID: https://orcid.org/0000-0001-5850-9107)
- Jing Yang (ORCID: https://orcid.org/0000-0003-0164-9699)
- He Xu (ORCID: https://orcid.org/0009-0000-3800-9957)
- Rong Tang (ORCID: https://orcid.org/0000-0001-7468-8424)
- Yanmei Guo (ORCID: https://orcid.org/0000-0003-2610-9154)
- Yamei Han
- Haoqi Pan
Institutions
- Shanghai Medical College of Fudan University (CN)
- Chinese Academy of Sciences (CN)
- Fudan University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Westlake University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai Cancer Institute (CN)
- Tianjin Institute of Industrial Biotechnology (CN)
Publication Details
- Journal
- Gut
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1136/gutjnl-2024-332782
- Citations
- 9
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.54
Funders
- National Natural Science Foundation of China